Announcement from IIQ on 5 Sept 2023
This annoucement is another positive step on the exosome front. ReseachDX have been working with IIQ on their SubB2M products. So the relationship must be working well for IIQ to expand that contract to include the exosome products.
The RDX website explains what ReseachDX do and why we would want to partner with them:
https://researchdx.com/company/
"Although pharmaceutical companies have well-established pathways for drug development, none exist for the co-development of FDA-approved companion diagnostics. In order to acquire the diagnostics expertise needed, biopharma must either outsource to multiple vendors or a large diagnostic company. If they outsource to multiple vendors, they must manage a complex process that is neither flexible nor dynamic. If they outsource to a large diagnostic company, diagnostic development will be limited to the company’s existing technology, product lines, and platforms, which may not be best suited for the companion diagnostic. The choice of platform also affects deployment in the clinical laboratories that may offer the test.
The ResearchDx business model reduces an over-burdensome process by virtue of its organizational structure without competing interests and allows for consideration of emerging molecular technologies in the development process."
So this relationship means IIQ can find the best commercial platform to maximise their SubB2M and Exo-Net products.
No change in valuation for me...just another box ticked on their way to commercialisation and revenue!
Parko
PS - Would love for someone to interrogate my IIQ Bull Case Straw.